Rigel Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Rigel Pharmaceuticals, Inc.‘s stocks are currently a part of 75 hedge funds’ portfolios, which represents 21.57% of the total amount of its stocks outstanding. This makes up a total of 37.18M shares of Rigel Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -66.03% or -72.25M shares fewer. As for the holding position changes, 24% (18) of current hedge fund investors increased the number of shares held, 32% (24) of current holders sold a part of the shares held, and 8% (6) closed the holdings completely. 7 hedge funds are new holders of Rigel Pharmaceuticals, Inc. stock in Q1 2023, it is 9.33% of total holders.
Hedge funds holding Rigel Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 128 |
|---|---|
| Q3 2018 | 133 |
| Q4 2018 | 128 |
| Q1 2019 | 126 |
| Q2 2019 | 123 |
| Q3 2019 | 127 |
| Q4 2019 | 129 |
| Q1 2020 | 121 |
| Q2 2020 | 132 |
| Q3 2020 | 135 |
| Q4 2020 | 143 |
| Q1 2021 | 147 |
| Q2 2021 | 156 |
| Q3 2021 | 157 |
| Q4 2021 | 157 |
| Q1 2022 | 159 |
| Q2 2022 | 131 |
| Q3 2022 | 134 |
| Q4 2022 | 119 |
| Q1 2023 | 75 |
Hedge funds changes in Rigel Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 30 | 58 | 20 | 15 | 5 |
|---|---|---|---|---|---|
| Q3 2018 | 22 | 50 | 33 | 17 | 11 |
| Q4 2018 | 13 | 52 | 32 | 17 | 14 |
| Q1 2019 | 15 | 39 | 29 | 17 | 26 |
| Q2 2019 | 12 | 46 | 31 | 9 | 25 |
| Q3 2019 | 17 | 38 | 35 | 13 | 24 |
| Q4 2019 | 18 | 45 | 36 | 15 | 15 |
| Q1 2020 | 8 | 34 | 49 | 15 | 15 |
| Q2 2020 | 18 | 51 | 33 | 6 | 24 |
| Q3 2020 | 22 | 36 | 50 | 19 | 8 |
| Q4 2020 | 24 | 42 | 51 | 17 | 9 |
| Q1 2021 | 25 | 42 | 55 | 19 | 6 |
| Q2 2021 | 25 | 47 | 48 | 15 | 21 |
| Q3 2021 | 16 | 58 | 42 | 15 | 26 |
| Q4 2021 | 26 | 43 | 54 | 26 | 8 |
| Q1 2022 | 19 | 49 | 54 | 16 | 21 |
| Q2 2022 | 10 | 35 | 53 | 35 | -2 |
| Q3 2022 | 21 | 44 | 34 | 20 | 15 |
| Q4 2022 | 15 | 38 | 39 | 30 | -3 |
| Q1 2023 | 7 | 18 | 24 | 6 | 20 |
Hedge funds changes in Rigel Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 831,000 | 782,000 |
|---|---|---|
| Q3 2018 | 788,000 | 1,433,000 |
| Q4 2018 | 1,729,000 | 881,000 |
| Q1 2019 | 916,000 | 335,000 |
| Q2 2019 | 835,000 | 362,000 |
| Q3 2019 | 104,000 | 73,000 |
| Q4 2019 | 16,000 | 89,000 |
| Q1 2020 | 48,000 | 51,000 |
| Q2 2020 | 44,000 | 49,000 |
| Q3 2020 | 980,000 | 1,692,000 |
| Q4 2020 | 2,509,000 | 2,148,000 |
| Q1 2021 | 2,203,000 | 2,160,000 |
| Q2 2021 | 3,432,000 | 3,608,000 |
| Q3 2021 | 3,316,000 | 2,886,000 |
| Q4 2021 | 1,078,000 | 1,191,000 |
| Q1 2022 | 1,347,000 | 750,000 |
| Q2 2022 | 1,188,000 | 584,000 |
| Q3 2022 | 579,000 | 165,000 |
| Q4 2022 | 1,022,350 | 25,150 |
| Q1 2023 | 155,022,000 | 12,409,000 |